--- title: "Abbott reports Q1 2026: Revenue $11.16B, adjusted diluted EPS $1.15; updates 2026 guidance" type: "News" locale: "en" url: "https://longbridge.com/en/news/282992899.md" description: "Abbott reported Q1 2026 results with revenue of $11.16 billion and adjusted diluted EPS of $1.15, a 6% increase year-over-year. The company completed its acquisition of Exact Sciences on March 23, 2026, and updated its 2026 guidance to 6.5%-7.5% sales growth and adjusted EPS of $5.38-$5.58. Abbott declared a quarterly dividend of $0.63 per share. Segment performance included a 9% growth in Established Pharmaceuticals and 8.5% in Medical Devices, while Nutrition saw a decline of 7.7%." datetime: "2026-04-16T11:43:00.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/282992899.md) - [en](https://longbridge.com/en/news/282992899.md) - [zh-HK](https://longbridge.com/zh-HK/news/282992899.md) --- # Abbott reports Q1 2026: Revenue $11.16B, adjusted diluted EPS $1.15; updates 2026 guidance Abbott reported first-quarter 2026 results with net sales of $11.164 billion and GAAP diluted EPS of $0.61; adjusted diluted EPS was $1.15, up 6% year-over-year. The company completed its acquisition of Exact Sciences on March 23, 2026, and updated full-year 2026 guidance to comparable sales growth of 6.5%–7.5% and adjusted diluted EPS of $5.38–$5.58 (including $0.20 of dilution from the acquisition). Abbott also declared its quarterly dividend of $0.63 per share. **Financial Highlights** - Revenue (Net Sales) — $11,164 million for Q1 2026, a 7.8% increase versus Q1 2025. - Gross margin (as reported) — Gross margin reported at $5,852 million for Q1 2026; adjusted gross margin excluding intangible amortization and other specified items shown as $6,284 million. - Operating earnings (Operating income) — $1,345 million for Q1 2026 (operating earnings declined vs. prior year). - Net earnings — GAAP net earnings of $1,077 million for Q1 2026; net earnings excluding specified items of $2,022 million. - Diluted EPS — GAAP diluted EPS $0.61; diluted EPS excluding specified items $1.15 (5.5% growth vs. adjusted prior year). Full-year 2026 adjusted diluted EPS guidance: $5.38 to $5.58 (includes $0.20 acquisition-related dilution). **Business Highlights** - Completed acquisition of Exact Sciences on March 23, 2026, establishing Abbott in the oncology diagnostics market and adding Cancer Diagnostics (including Cologuard and Cancerguard) to the Diagnostics segment. - Reported comparable sales growth of 3.7% for the company; segment comparable performance included Nutrition (comparable decline of 7.7%), Diagnostics (comparable growth of 1.8%), Established Pharmaceuticals (comparable growth of 9.0%), and Medical Devices (comparable growth of 8.5%). - Medical Devices delivered broad-based operational strength with double-digit reported growth in Electrophysiology, Heart Failure and Rhythm Management, and continued momentum in Diabetes Care continuous glucose monitors. - Diagnostics performance: Core Laboratory tests increased year-over-year and sequentially; Rapid and Molecular Diagnostics were affected by a weaker respiratory virus season; Cancer Diagnostics growth driven by Cologuard and a multi-cancer screening test launched last year. - Product and clinical progress: announced collaboration with AtaCor Medical on next-generation EV-ICD system; VERITAS study showed positive early results for the Amulet 360 LAA Occluder; FreeDM2 trial showed clinical benefit for FreeStyle Libre in Type 2 diabetes on basal insulin. Original SEC Filing: ABBOTT LABORATORIES \[ ABT \] - 8-K - Apr. 16, 2026 **Disclaimer** This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC. ### Related Stocks - [ABT.US](https://longbridge.com/en/quote/ABT.US.md) - [EXAS.US](https://longbridge.com/en/quote/EXAS.US.md) - [LABU.US](https://longbridge.com/en/quote/LABU.US.md) - [IHE.US](https://longbridge.com/en/quote/IHE.US.md) - [VHT.US](https://longbridge.com/en/quote/VHT.US.md) - [IDNA.US](https://longbridge.com/en/quote/IDNA.US.md) - [XLV.US](https://longbridge.com/en/quote/XLV.US.md) - [BBH.US](https://longbridge.com/en/quote/BBH.US.md) - [IBB.US](https://longbridge.com/en/quote/IBB.US.md) - [PBE.US](https://longbridge.com/en/quote/PBE.US.md) - [IHF.US](https://longbridge.com/en/quote/IHF.US.md) - [XBI.US](https://longbridge.com/en/quote/XBI.US.md) - [FBT.US](https://longbridge.com/en/quote/FBT.US.md) - [IHI.US](https://longbridge.com/en/quote/IHI.US.md) - [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md) - [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md) - [XHE.US](https://longbridge.com/en/quote/XHE.US.md) - [LABD.US](https://longbridge.com/en/quote/LABD.US.md) - [IXJ.US](https://longbridge.com/en/quote/IXJ.US.md) - [BIB.US](https://longbridge.com/en/quote/BIB.US.md) ## Related News & Research - [NVision Expands from Quantum Sensing to Quantum Computing to Accelerate Discovery and Validation of New Therapies](https://longbridge.com/en/news/286239950.md) - [Rayburn West Financial Services LLC Buys Shares of 16,587 Abbott Laboratories $ABT](https://longbridge.com/en/news/286395934.md) - [Eton Secures U.S. IMPAVIDO Rights; $4.25M Fees, Up To $4M Milestones And 50-55% Revenue Share](https://longbridge.com/en/news/286966420.md) - [NeOnc Advances Glioma Programs and Strengthens Financial Position](https://longbridge.com/en/news/286826865.md) - [Full Transcript: Cellectar Biosciences Q1 2026 Earnings Call](https://longbridge.com/en/news/286422585.md)